📣 VC round data is live. Check it out!

enGene Valuation Multiples

Discover revenue and EBITDA valuation multiples for enGene and similar public comparables like Prothena Corp., TTY Biopharm, Forte Biosciences, Luzhu Biotech and more.

enGene Overview

About enGene

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.


Founded

2023

HQ

Canada

Employees

82

Website

engene.com

Financials (FY)

Revenue:
Net Income:

EV

$330M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

enGene Stock Performance

enGene has current market cap of $572M, and enterprise value of $330M.

Market Cap Evolution


enGene's stock price is $8.54.

enGene share price increased by 122.4% in the last year.

See more trading valuation data for enGene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$330M$572M0.0%-15.5%122.4%

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

enGene Valuation Multiples

enGene Financial Valuation Multiples

As of May 5, 2026, enGene has market cap of $572M and EV of $330M.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified enGene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

enGene Competitors

enGene competitors include Prothena Corp., TTY Biopharm, Forte Biosciences, Luzhu Biotech, Boan Biotech, Tectonic Therapeutic, Boiron, Altimmune, Supriya Lifescience and Avalon Pharma.

Most enGene public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Prothena Corp.29.1x7.7x(1.5x)
TTY Biopharm2.6x2.5x7.0x
Forte Biosciences(7.2x)
Luzhu Biotech17.4x(27.0x)(170.5x)
Boan Biotech4.4x4.3x26.0x42.2x
Tectonic Therapeutic(4.3x)
Boiron0.9x6.8x
Altimmune8516.7x12003.7x(4.0x)(3.2x)

This data is available for Pro users. Sign up to see all enGene competitors and their valuation data.

Start Free Trial

enGene Funding History

Before going public, enGene raised $25M in total equity funding, across 2 rounds.


enGene Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-15Series BFonds de solidarité FTQ; Forbion Capital Partners; Inbio Ventures; Lumira Ventures; Pharmstandard$12MenGene Inc., a Montréal-based biotechnology company, develops an innovative platform technology for delivering genes to cells lining the gastrointestinal tract. The company focuses on DNA-based therapeutics, with its lead product EG-12 consisting of carrier-DNA complexes for gut-localized expression of IL-10 to treat ulcerative colitis. On January 26, 2015, enGene closed a CAD 13.5 million (EUR 9.6 million, US$11.5 million) Series B financing round led by Forbion Capital Partners, with participation from Fonds de solidarité FTQ, Pharmstandard International S.A., and existing investor Lumira Capital via its Merck Lumira Biosciences Fund. Proceeds fund advancement of EG-12 into phase I/II clinical trials. Sander van Deventer from Forbion joined enGene's Board of Directors, bringing expertise in IBD and gene therapy.
Nov-13Series ALumira Ventures$13MenGene is a pre-clinical stage biopharmaceutical company developing a platform technology for the robust delivery of nucleotides (DNA or RNA) to the gut. In August 2013, it completed an initial closing of a $13.25 million financing led by Lumira Capital via its Merck Lumira Biosciences Fund. The funds enabled enGene to relocate its headquarters to Montreal, Quebec, and progress toward clinical stage development.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About enGene

When was enGene founded?enGene was founded in 2023.
Where is enGene headquartered?enGene is headquartered in Canada.
How many employees does enGene have?As of today, enGene has over 82 employees.
Who is the CEO of enGene?enGene's CEO is Ronald Harold Wilfred Cooper.
Is enGene publicly listed?Yes, enGene is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of enGene?enGene trades under S0N ticker.
When did enGene go public?enGene went public in 2023.
Who are competitors of enGene?enGene main competitors include Prothena Corp., TTY Biopharm, Forte Biosciences, Luzhu Biotech, Boan Biotech, Tectonic Therapeutic, Boiron, Altimmune, Supriya Lifescience, Avalon Pharma.
What is the current market cap of enGene?enGene's current market cap is $572M.
Is enGene profitable?No, enGene is not profitable.
How many companies enGene has acquired to date?enGene hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies enGene has invested to date?enGene hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to enGene

Lists including enGene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial